Evaluation of the relative severity of pulmonary neutrophilic inflammation and therapeutic modification with IV Prolastin by means of 18 FDG PET/CT scanning in subjects with alpha1-antitrypsin deficiency. - ECLIPSE AATD

HB NHS Foundation Trust0 个研究点目标入组 26 人开始时间: 2008年4月4日最近更新: 2019年11月25日

适应症

试验速览

暂无简介。

•Three subject groups of individuals over the age of 50 years will be studied.
•Healthy never smokers age 50-70 years, no evidence of lung disease, FEV1>75% predicted, FEV1/VC>70%, no relevant medical or mental disorder, able to give informed consent.
•Patients with an emphysema COPD phenotype (and normal alpha 1-antitrypsin phenotype), no other active lung disease, FEV1<75% predicted, FEV1/VC<70%, KCO<80% predicted (or known emphysema on previous CT scan), fewer than two acute exacerbation in the previous 12 months and no recent exacerbations, no smoking history within the preceding 12 months, no other relevant medical or mental disorder, able to give informed consent.
•Patients with an emphysema COPD phenotype (PiZ alpha 1-antitrypsin phenotype, no other active lung disease, FEV1<75% predicted, FEV1/VC<70%, KCO<80% predicted (or known emphysema on previous CT scan), fewer than two acute exacerbation in the previous 12 months and no recent exacerbations, no smoking history within the preceding 12 months, no other relevant medical or mental disorder, able to give informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

发起方

HB NHS Foundation Trust